CSL Limited (CSL.AX)
ValueMarkers Composite Index
57% below intrinsic value ($320)
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
Deep Dive Analysis
DCF Analysis
Intrinsic value estimate, margin of safety, and key valuation metrics.
Piotroski F-Score
9-point financial strength test across profitability, leverage, and efficiency.
Quality Triple Check
Piotroski F-Score + Altman Z-Score + Beneish M-Score combined assessment.
Valuation Analysis
Complete multiples breakdown - P/E, P/B, EV/EBITDA, yield metrics, and intrinsic value.